首页> 美国卫生研究院文献>Neuro-Oncology >P06.13OUTCOME AND PROGNOSTIC FACTORS IN ATYPICAL AND MALIGNANT MENINGIOMA: UNIVERSITY OF FLORENCE EXPERIENCE
【2h】

P06.13OUTCOME AND PROGNOSTIC FACTORS IN ATYPICAL AND MALIGNANT MENINGIOMA: UNIVERSITY OF FLORENCE EXPERIENCE

机译:P06.13非典型和恶性脑膜瘤的结果和预后因素:佛罗伦萨大学经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: This study aim to retrospectively assess prognostic factors and outcome in 68 patients with atypical and malignant meningiomas. MATERIAL AND METHODS: Data of 68 patients affected by meningioma between january 1993 and december 2011 were retrospective analyzed. In 80 % of the patients surgical resection was macroscopical; in 51 patients histology resulted atypical and in 17 malignant. All patients performed radiation treatment, of them 56% after surgical resection, 26% at the first relapse and 18% at the secon relapse, mean dose delivered was 54.6 Gy. RESULTS: Median follow-up was 6.7 years, (range 1.5-19.9 years). The actuarial overall survival rates at 5- and 10-year were 74.1 and 45.6 %, respectively. At univariate analysis age >60 years and radiotherapy dose >52 Gy showed statistical significance, (p = 0.04 and p = 0.03, respectively). At the multivariate analysis only radiotherapy dose >52 Gy maintained the statistical significance, (p = 0.037). The 5- and 10-year disease-free survival rates were 76.5 and 69.5 % respectively, on univariate analysis they were significantly influenced by size >5 cm (p = 0.04) and grading (p = 0.003), both still remained significant prognostic factors at multivariate analysis (p = 0.044 and p = 0.0006, respectively). Treatment related toxicities were limited: 16 % of the patients experienced grade ≤ 2 acute side effects, no ≥ grade 3 acute toxicity was exeperienced. CONCLUSIONS: In study, age and radiotherapy dose were associated with a longer overall survival, while disease free survival was influenced by preoperative size and grading of the tumor . Although there were some advantages in terms of overall survival for patients treated with postoperative radiotherapy, the benefit did not reach the significance. Multicenter prospective studies are necessary to clarify the management and the correct timing of radiotherapy in such a rare disease.
机译:目的:本研究旨在回顾性评估68例非典型和恶性脑膜瘤患者的预后因素和预后。材料与方法:回顾性分析1993年1月至2011年12月期间68例脑膜瘤患者的资料。在80%的患者中,手术切除是宏观的; 51例患者的组织学结果为非典型,17例为恶性肿瘤。所有患者均进行了放射治疗,其中手术切除后占56%,第一次复发占26%,继发性复发占18%,平均给药剂量为54.6 Gy。结果:中位随访时间为6.7年(范围1.5-19.9年)。 5年和10年的精算总生存率分别为74.1%和45.6%。在单变量分析年龄> 60岁和放疗剂量> 52 Gy时显示统计学显着性(分别为p = 0.04和p = 0.03)。在多变量分析中,仅> 52 Gy的放疗剂量保持统计学意义(p = 0.037)。 5年和10年无病生存率分别为76.5%和69.5%,单因素分析显示,它们受到大于5 cm的大小(p = 0.04)和分级(p = 0.003)的显着影响,两者仍然仍然是重要的预后因素多变量分析时(分别为p = 0.044和p = 0.0006)。与治疗有关的毒性是有限的:16%的患者经历了≤2级的急性副作用,没有≥3级的急性毒性。结论:在研究中,年龄和放疗剂量与更长的总生存期有关,而无病生存期则受术前肿瘤大小和肿瘤分级的影响。尽管在术后放射治疗的患者的总生存率方面有一些优势,但这种优势并未达到显着性。需要进行多中心前瞻性研究来阐明这种罕见疾病的治疗方法和放疗的正确时机。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号